Advancements in the co-formulation of biologic therapeutics

dc.creatorChauhan, Veeren M.
dc.creatorZhang, Hongyu
dc.creatorDalby, Paul A.
dc.creatorAylott, Jonathan W.
dc.date.accessioned2020-09-02T14:49:33Z
dc.date.accessioned2022-09-23T18:04:16Z
dc.date.available2020-09-02T14:49:33Z
dc.date.available2022-09-23T18:04:16Z
dc.date.created2020-09-02T14:49:33Z
dc.identifier0168-3659
dc.identifierhttps://doi.org/10.1016/j.jconrel.2020.08.013
dc.identifierhttp://hdl.handle.net/20.500.12010/12585
dc.identifierhttps://doi.org/10.1016/j.jconrel.2020.08.013
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3494453
dc.description.abstractBiologic therapeutics are the medicines of the future and are destined to transform the approaches by which the causes and symptoms of diseases are cured and alleviated. These approaches will be accelerated through the development of novel strategies that target multiple pharmacologically active sites using a combination of different biologics, or mixtures of biologics and small molecule therapeutics. However, for this potential to be realised, advancements in co-formulation strategies for biologic therapeutics must be established. This review describes the current and emerging developments within this field and highlights the challenges and potential solutions, that will pavethe-way towards their clinical translation.
dc.languageeng
dc.publisherJournal of Controlled Release
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.rightsAcceso restringido
dc.sourcereponame:Expeditio Repositorio Institucional UJTL
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozano
dc.subjectTargeted
dc.subjectBiologic
dc.subjectCo-formulation
dc.subjectActive pharmaceutical ingredients
dc.subjectProteins
dc.subjectNucleic acids
dc.subjectVaccines
dc.titleAdvancements in the co-formulation of biologic therapeutics


Este ítem pertenece a la siguiente institución